{"disease":{"id":"benign-brain-tumors","name":"benign brain tumors"},"drugs":{"marketed":[],"pipeline":[],"offLabel":[],"totalMarketed":0,"totalPipeline":0},"trials":{"data":[{"nct_id":"NCT04584086","title":"Changes in the MRI Signal in Patients With Benign Tumors of the Brain and Meninges Treated With Proton Therapy: Impact of TEL and the Biological Dose Received","phase":"NA","overall_status":"COMPLETED","enrollment_count":20,"lead_sponsor_name":"Centre Francois Baclesse","has_results":false},{"nct_id":"NCT06322342","title":"Phase 2 Ascending Dose Safety and Efficacy Study of RVP-001, a Manganese-based MRI Contrast Agent","phase":"PHASE2","overall_status":"COMPLETED","enrollment_count":18,"lead_sponsor_name":"Reveal Pharmaceuticals Inc.","has_results":false}],"total":2},"guidelines":[],"source":"Drug Landscape verified database"}